WallStSmart

Merck & Company Inc (MRK)vsOrganogenesis Holdings Inc (ORGO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 14452% more annual revenue ($66.57B vs $457.45M). MRK leads profitability with a 4.8% profit margin vs -18.4%. ORGO earns a higher WallStSmart Score of 41/100 (D).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

ORGO

Hold

41

out of 100

Grade: D

Growth: 6.0Profit: 2.5Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 3.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Intrinsic value data unavailable for ORGO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

ORGO4 strengths · Avg: 9.8/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

EPS GrowthGrowth
555.0%10/10

Earnings expanding 555.0% YoY

Altman Z-ScoreHealth
3.3010/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.239/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

ORGO4 concerns · Avg: 2.8/10
Market CapQuality
$220.03M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.7%3/10

ROE of 0.7% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Revenue GrowthGrowth
-56.7%2/10

Revenue declined 56.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : ORGO

The strongest argument for ORGO centers on Price/Book, EPS Growth, Altman Z-Score.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : ORGO

The primary concerns for ORGO are Market Cap, Return on Equity, Piotroski F-Score.

Key Dynamics to Monitor

MRK profiles as a value stock while ORGO is a turnaround play — different risk/reward profiles.

ORGO carries more volatility with a beta of 1.29 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

ORGO scores higher overall (41/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Organogenesis Holdings Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.

Want to dig deeper into these stocks?